Skip to main content
OpenTrials

Clinical trial condition

Non-Hodgkin Lymphoma

Explore clinical trials studying Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

218 public trials 63 recruiting studies
Refine in advanced search Browse all conditions

Non-Hodgkin Lymphoma trial results

Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT03666000

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Chronic Disease, +27 more
Locations
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Winship Cancer Institute Emory University Atlanta, Georgia, United States
  • Northside Hospital Cancer Institute Atlanta, Georgia, United States
  • University of Maryland Baltimore, Maryland, United States
View all 15 locations
View Trial Details
Recruiting

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

NCT07652580

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune Dysregulation, +12 more
Locations
  • Uniformed Services University of the Health Sciences Bethesda, Maryland, United States
  • Walter Reed National Military Medical Center Bethesda, Maryland, United States
  • Naval Medical Center Portsmouth Portsmouth, Virginia, United States
View Trial Details
Recruiting

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT05826535

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations
  • University of California-Irvine Medical Center Irvine, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of California, Los Angeles (UCLA) Medical Center Los Angeles, California, United States
  • Scripps Clinic San Diego, California, United States
View all 35 locations
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
View all 115 locations
View Trial Details
Recruiting

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

NCT07249528

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Memorial Sloan Kettering Monmouth (Consent only) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Consent Only) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Westchester (Consent only) Harrison, New York, United States
  • Weill Cornell Medical Center (Data Analysis Only) New York, United States
View Trial Details

Related conditions